as per annexure enclosed
Awaiting price reaction for this filing.
Apollo Hospitals' Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. On a consolidated basis, revenue from operations grew to Rs. 21,794 crores (up ~14% from Rs. 19,059 crores in FY24), while profit after tax jumped to Rs. 1,505 crores from Rs. 935 crores (~61% growth). Standalone revenue rose to Rs. 8,202 crores (vs Rs. 7,274 crores) with PAT of Rs. 1,296 crores (~28% growth) and EBITDA of Rs. 2,044 crores. The Board declared a final dividend of Rs. 10 per share (200%) taking total FY25 dividend to Rs. 19 per share (380%), with AGM scheduled on August 29, 2025. CRISIL and India Ratings reaffirmed the company's AA+/Stable rating, and qualified borrowings reduced from Rs. 1,956 crores to Rs. 1,783 crores. The Board also approved re-appointment of Executive Directors Preetha Reddy, Suneeta Reddy, Sangita Reddy for five years, new Secretarial Auditors, and a Rs. 285 crore hospital acquisition.
Strong FY25 performance with double-digit revenue growth and robust PAT expansion signals healthy business momentum; the higher total dividend (380% vs prior year) rewards shareholders, and AA+ rating reaffirmation with falling borrowings reinforces financial strength. The Rs. 285 crore hospital acquisition and large capex (Rs. 1,712 crores in investing activities on consolidated basis) indicate continued expansion, which could pressure margins in the near term.